Table 1.

Correlations of MAPK4 expression with clinical characteristics of patients with NSCLC.

Characteristics	Total	MAPK4 in cancer		χ 2	p
		Low	High
Age (years)
≥60	55	25	30	1.212	0.271
<60	33	19	14
Sex
Male	49	22	27	1.151	0.283
Female	39	22	17
Histological grade
I/II	56	28	28	0.000	1.000
III	32	16	16
T
T1–2	57	26	31	0.281	0.596
T3–4	19	10	9
N
N0	34	14	20	0.720	0.396
N1–3	33	17	16
Tumor size
≥5	19	10	9	0.281	0.596
<5	57	26	31
Clinical stage
I–II	39	17	22	0.433	0.511
III–IV	25	13	12
ALK
Negative	72	35	37	0.446	0.307
Positive	9	6	3
EGFR
Negative	67	31	36	1.564	0.211
Positive	21	13	8

Abbreviations: ALK, anaplastic lymphoma kinase; CDK, cyclin‐dependent kinase; EGFR, epidermal growth factor receptor; MAPK4, mitogen‐activated protein kinase 4; NSCLC, non‐small cell lung cancer.